FOXP3 and Hodgkins lymphoma: Increased FoxP3 expression and Treg cell elevation are generally considered to be poor outcome markers in various cancers, including Hodgkin’s lymphoma, follicular lymphoma, breast cancer, gastric malignancies, and ovarian cancers [27], [28], [29], [30], [31].